Delivery Order SPE2DB22D1017-SPE2DB24FG3KY

Award Date 8/16/24
Potential Completion Date 8/19/24
Potential Value $24K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $38,483.71, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Biktarvy 50-200-25 mg tablet, a HIV medication. The contract is a firm-fixed price delivery order with an ultimate completion date of April 24, 2025. This award is not associated with a set-aside program and is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999.00 that...
This federal contract award is a delivery order placed by the Defense Logistics Agency (DLA) with AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $42,417.77, is for the supply of Biktarvy 50-200-25 mg tablets, a medication used in the treatment of HIV. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $44,018.11, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Biktarvy 50-200-25 mg tablets, a prescription medication used in the treatment of HIV. The contract is a Firm Fixed Price Delivery Order that runs through July 17, 2024. It is not associated with any set-aside designation, indicating open competition....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Biktarvy 50-200-25 mg tablets, a medication used to treat HIV. The contract has a ceiling value of $53,548.74 and an ultimate completion date of April 26, 2023. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA...
The U.S. Defense Logistics Agency (DLA) awarded a $64,726.44 firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4,565,551,030 units of the HIV medication BIKTARVY 50-200-25 mg tablet. The contract has an ultimate completion date of August 23, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December...
This federal contract award, with a value of $62,444.69, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Biktarvy 50-200-25 mg tablets, a medication used to treat HIV. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to...
This federal contract award, valued at $17,986.86, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Biktarvy 50-200-25 mg tablets, a brand-name HIV medication. This is a Firm Fixed Price delivery order contract with a period of performance through May 14, 2025. The contract is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
This is a firm fixed-price delivery order issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Biktarvy 50-200-25 mg tablets, a medication used to treat HIV. The contract has a ceiling value of $53,868.66 and a period of performance through April 24, 2025. This award is not set aside and represents open competition. Amerisourcebergen Drug Corp is the prime...
This federal contract award, valued at $48,694.13, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BIKTARVY 50-200-25 MG TABLET, a medication used in the treatment of human immunodeficiency virus (HIV) infection. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $97,221.66, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Biktarvy 50-200-25 mg tablets, a specialty medication used to treat HIV infection. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen's parent company, Cencora, Inc., holds...
  • SPE2DB22D1017
    Indefinite Delivery Contract
  • SPE2DB22D1017-SPE2DB24FG3KY
    Delivery Order

This federal contract award, valued at $23,552.32, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor. The contract is for the delivery of Biktarvy 50-200-25 mg tablets, a specialty HIV medication, to support various government healthcare programs.

The contract is a delivery order awarded under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a total potential value of up to $999,999,999 through December 2025. This IDC enables the DLA to efficiently procure a comprehensive range of medical commodities, including prescription drugs and medical supplies, from Amerisourcebergen to support military treatment facilities and other federal healthcare providers nationwide. The contract does not have a set-aside designation and is scheduled for completion by August 19, 2024.

Generated 11/15/24, 9:02 AM